Patients taking Novo Nordisk's Wegovy obesity treatment maintained an average of 10% weight loss after four years, ...

Novo Nordisk's (NVO) obesity therapy Wegovy cut adverse kidney-related events by 22% in obese and overweight individuals in a ...

LONDON, May 14 (Reuters) - Patients taking Novo Nordisk's popular Wegovy obesity treatment maintained an average of 10% weight loss after four years on the treatment, the company said on Tuesday. Novo ...

The results shed light on the long-term effects of Wegovy, and could boost Novo Nordisk's case to insurers and governments to ...

The data could potentially bolster Novo's case for Wegovy as it attempts to convince insurers and governments to cover the ...

Presented at this week’s European Congress on Obesity, the two studies also demonstrate that Novo Nordisk’s Wegovy ...

Amid the growing popularity of drugs used for weight loss like Ozempic, Wegovy, Mounjaro and Zepbound, one question has ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Patients taking Novo Nordisk’s anti-obesity jab sustained weight loss for up to four years and had a ...

Patients taking Novo Nordisk's obesity drug Wegovy maintained an average of 10% weight loss for up to four years, according to a new analysis from the longest clinical trial to date on the treatment.

LONDON, May 14 (Reuters) - Patients taking Novo Nordisk's popular Wegovy obesity treatment maintained an average of 10% weight loss after four years on the treatment, the company said on Tuesday.

(Updates shares in paragraph 6, side effects in paragraph 12) By Maggie Fick LONDON, May 14 (Reuters) - Patients taking Novo Nordisk's Wegovy obesity treatment maintained an average of 10% weight ...

Novo Nordisk (NVO) stock was trading down Thursday despite strong first quarter results, beating Wall Street consensus, led by the blockbuster GLP-1s Ozempic for diabetes and Wegovy for weight loss.